Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Bednarek, Marcin" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Levels of renalase and advanced oxidation protein products with regard to catecholamines in haemodialysed patients
Autorzy:
Dziedzic, Marcin
Orłowska, Ewelina
Petkowicz, Beata
Bednarek-Skublewska, Anna
Solski, Janusz
Goździewska, Małgorzata
Powiązania:
https://bibliotekanauki.pl/articles/991106.pdf
Data publikacji:
2017
Wydawca:
Instytut Medycyny Wsi
Tematy:
renalase
advanced oxidation protein products
catecholamines
haemodialysis
Opis:
Introduction. The main mediators of the sympathetic nervous system in the effectors part are catecholamines (CA). An increased sympathetic nerve activity observed in chronic kidney disease (CKD), is due to a raised level of CA in plasma. Renalase is a protein secreted by the kidneys, composed of 342 amino acids, which is able to metabolize the circulating CA and possibly play an important role in the regulation of sympathetic tone and blood pressure. Also, oxidative stress, defined as a disruption of the equilibrium between the generation of oxidants, is a crucial factor in the development of the inflammatory syndrome associated with CKD. The advanced oxidation protein products (AOPP) represent exquisite markers of phagocyte-derived oxidative stress. Objective. The aim of the study was to investigate the concentration of renalase and explore the associations between AOPP with regards to CA in haemodialysis (HD) patients. Materials and method. The study was conducted among 50 residents of the municipality and neighbouring villages in the province of Lublin, central-eastern Poland. Results. In the studied patients, it was found that an average concentration of renalase was 44.8 ± 6.5 μg/mL, whereas of AOPP plasma levels – 57.5 ± 21.5 μmol/L. The results demonstrated the correlation between levels of renalase and AOPP in the HD patients. Indeed, elevated levels of renalase and AOPP in HD may be due to the presence of uremic toxins in blood. The concentration of urea affects the plasma concentrations of AOPP and renalase causing a direct relationship between renalase and AOPP. However, there is no clear relationship between renalase and circulating catecholamines in HD patients.
Źródło:
Annals of Agricultural and Environmental Medicine; 2017, 24, 3
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Stereotactic management of arrhythmia - radiosurgery in treatment of ventricular tachycardia (SMART-VT) - clinical trial protocol and study rationale
Autorzy:
Miszczyk, Marcin
Jadczyk, Tomasz
Tomasik, Bartłomiej
Latusek, Tomasz
Bednarek, Jacek
Kurzelowski, Radosław
Gołba, Krzysztof
Wojakowski, Wojciech
Wita, Krystian
Dolla, Łukasz
Grządziel, Aleksandra
Blamek, Sławomir
Powiązania:
https://bibliotekanauki.pl/articles/2032986.pdf
Data publikacji:
2020
Wydawca:
Medical Education
Tematy:
ventricular tachycardia
ablation
radiosurgery
STAR
arrhythmia
Opis:
Patients with ventricular tachycardia are usually treated with antiarrhythmic drugs and ablation if the arrhythmia substrate is available for invasive treatment. Despite high efficiency of this treatment there is a significant group of patients who do not benefit from available treatment methods, either because they cannot be applied or do not allow for durable control of the disease. For that reason a novel treatment method, STereotactic Arrhythmia Radioablation (STAR) has been proposed and its safety and efficiency is extensively studied throughout the world. The method is based on irradiation of the arrhythmia substrate identified with electrophysiological examination with high-precision image-guided radiosurgical methods usually used for ablation of malignant tumors. Here we present the protocol of the first Polish study on STAR in patients with intractable ventricular tachycardia (STAR-VT, NCT04642963), designed to test the safety of the method. Secondary endpoints include measures of the treatment efficiency.
Źródło:
OncoReview; 2020, 10, 4; 123-129
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies